Investigators in the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering have one foot in the lab and one foot in the clinic. Positioned at the forefront of translational research, HOPP investigators are uniquely situated to bridge gaps between the basic science and clinical research worlds. HOPP’s research programs span multiple cancer types, and its scientists employ innovative technologies, often redefining how we find, develop, and test new cancer therapies. The program also supports graduate and postdoctoral training for physicians and scientists who want to serve at the cutting-edge of translational cancer research.

View Our Timeline of Discoveries

charles sawyers

HOPP Chair Charles Sawyers (center) with research fellows Ping Mu and Elizabeth Adams


Faculty & Leadership

HOPP scientists are leaders in their field and are conducting research at the cutting edge of cancer science.

View all HOPP faculty View our scientific advisory board

Education & Training

HOPP is dedicated to training physicians and scientists at all levels for careers at the forefront of translational cancer research.

Open Positions

Explore open postdoctoral positions and other career opportunities.

Learn more

Featured News & Events

View all news View all events

In The Clinic

Analyzing Spinal Fluid Could Guide Brain Tumor Diagnosis and Treatment

Cancer DNA taken from spinal fluid could serve as a liquid biopsy that provides information on brain tumor mutations.


Tumor Mutational Burden Can Help Predict Response to Immunotherapy in Many Different Cancers

Investigators confirmed that people whose tumors have a high tumor mutational burden and were treated with immunotherapy lived longer.

In the Lab

What Was MSK’s Role in TCGA, the Groundbreaking Cancer Genomic Study?

The multicenter project, which yielded dozens of scientific papers on more than 30 different kinds of cancer, has officially drawn to a close.

In the Lab

Researchers Identify Why Women May Develop Resistance to a New Class of Breast Cancer Drugs

Clues emerge about why promising new breast cancer drugs sometimes don’t work — and what might be done about it.